AI Article Synopsis
Article Abstract
Chimeric fusion genes are highly prevalent in childhood acute lymphoblastic leukemia (ALL) and are mostly prenatal, early genetic events in the evolutionary trajectory of this cancer. ETV6-RUNX1-positive ALL also has multiple ( approximately 6 per case) copy number alterations (CNAs) as revealed by genome-wide single-nucleotide polymorphism arrays. Recurrent CNAs are probably "driver" events contributing critically to clonal diversification and selection, but at diagnosis, their developmental timing is "buried" in the leukemia's covert natural history. This conundrum can be resolved with twin pairs. We identified and compared CNAs in 5 pairs of monozygotic twins with concordant ETV6-RUNX1-positive ALL and 1 pair discordant for ETV6-RUNX1 positive ALL. We compared, within each pair, CNAs classified as potential "driver" or "passenger" mutations based upon recurrency and, where known, gene function. An average of 5.1 (range 3-11) CNAs (excluding immunoglobulin/T-cell receptor alterations) were identified per case. All "driver" CNAs (total of 32) were distinct within each of the 5 twin pairs with concordant ALL. "Driver" CNAs in another twin with ALL were all absent in the shared ETV6-RUNX1-positive preleukemic clone of her healthy co-twin. These data place all "driver" CNAs secondary to the prenatal gene fusion event and most probably postnatal in the sequential, molecular pathogenesis of ALL.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1182/blood-2009-10-251413 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Genomic differences of patients with hematologic malignancies in different age groups.
Commun Biol
December 2024
Department of Hematology, Peking University First Hospital, Beijing, China.
Article Synopsis
- Hematologic malignancies significantly impact the health of children, young adults, and older adults, yet their biological causes are not well understood.
- A study revealed notable differences in clinical features and genomic mutations between children/young adults (CYAs) and older adults (OAs) in these diseases, including lower mutational burdens in CYAs for many key genes.
- The research identified specific genes with varying mutation rates and emphasized the need for age-oriented personalized treatment options based on the distinct genetic and clinical landscapes of CYAs and OAs.
Driver mutations associated with signatures of platinum sensitivity in germ cell tumors.
NPJ Precis Oncol
November 2024
Department of Urology, University of California San Diego, La Jolla, CA, USA.
Article Synopsis
- - The study analyzed genomic and transcriptomic data from 138 germ cell tumors to find out why some tumors resist treatment with cisplatin, a common chemotherapy drug.
- - They focused on specific genetic mutations (like KRAS, TP53, and KIT) and patterns in gene copies that might contribute to this resistance, observing that certain mutations were more common in primary tumors compared to metastatic ones.
- - The research found that tumors with platinum-resistant alterations had lower transcriptomic scores linked to sensitivity to cisplatin, indicating a possible connection between these genetic changes and treatment resistance.
Genomic landscape of cutaneous, acral, mucosal, and uveal melanoma in Japan: analysis of clinical comprehensive genomic profiling data.
Int J Clin Oncol
December 2024
Department of Dermatology, Sapporo Medical University School of Medicine, South 1, West 16, Chuo-ku, Sapporo, 060-8543, Japan.
Article Synopsis
- This study examines the differences in melanoma types (cutaneous, acral, mucosal, and uveal) and their genetic profiles among Japanese patients, highlighting the prevalence of acral and mucosal melanoma, which are often resistant to standard therapies.
- A total of 380 melanoma cases were analyzed, revealing that the tumor mutational burden (TMB) across different melanoma types was similar, with key driver mutations identified in each type showing genetic variations specific to their classifications.
- The research concludes that the unique genomic characteristics and lower TMB in Japanese patients indicate poorer treatment outcomes, emphasizing the urgent need for more effective therapies tailored to this population.
Large-scale copy number alterations are enriched for synthetic viability in BRCA1/BRCA2 tumors.
Genome Med
August 2024
Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Article Synopsis
- Pathogenic mutations in the BRCA1 and BRCA2 genes are linked to several types of hereditary cancer, but inactivating both copies (bBRCA1/2) can be lethal in embryos and reduce cell growth.
- Researchers identified specific genetic changes commonly found in bBRCA1/2 tumors that could boost cell proliferation and studied them through various analytical methods, including examining mutation patterns in databases.
- In their results, they discovered that bBRCA1/2 tumors often showed large genomic deletions, identified genes that influenced cell growth, and validated some candidate genes (like RIC8A) as crucial for tumor viability despite the loss of BRCA1 and BRCA2.
Improved allele-specific single-cell copy number estimation in low-coverage DNA-sequencing.
Bioinformatics
August 2024
School of Computing, University of Connecticut, Storrs, CT 06082, United States.
Motivation: Advances in whole-genome single-cell DNA sequencing (scDNA-seq) have led to the development of numerous methods for detecting copy number aberrations (CNAs), a key driver of genetic heterogeneity in cancer. While most of these methods are limited to the inference of total copy number, some recent approaches now infer allele-specific CNAs using innovative techniques for estimating allele-frequencies in low coverage scDNA-seq data. However, these existing allele-specific methods are limited in their segmentation strategies, a crucial step in the CNA detection pipeline.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!